Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines

Multiple kinase inhibitors are available for patients with advanced hepatocellular carcinoma (HCC). It is largely unknown whether regorafenib or lenvatinib modulates innate immunity including Toll-like receptor (TLR)-signaling pathways in HCC. We performed real-time RT-PCR to investigate 84 TLR-asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Reina, Kanda, Tatsuo, Fujisawa, Mariko, Matsumoto, Naoki, Masuzaki, Ryota, Ogawa, Masahiro, Matsuoka, Shunichi, Kuroda, Kazumichi, Moriyama, Mitsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246870/
https://www.ncbi.nlm.nih.gov/pubmed/32397371
http://dx.doi.org/10.3390/ijms21093349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246870/
https://www.ncbi.nlm.nih.gov/pubmed/32397371
http://dx.doi.org/10.3390/ijms21093349

Ejemplares similares